US2005187271A1PendingUtilityA1

Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or its physiologically tolerable salts as a cancer-fighting agent

Assignee: TROMMSDORFF GMBH & CO KGPriority: Feb 15, 2000Filed: Apr 29, 2005Published: Aug 25, 2005

Est. expiryFeb 15, 2020(expired)· nominal 20-yr term from priority

Inventors:Rudy Susilo Hans Rommelspacher

A61K 31/426A61P 43/00A61P 35/00

PatentIndex Score

Cited by

References

Claims

Abstract

Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts for the treatment and/or prevention of cancer.

Claims

exact text as granted — not AI-modified

1 . A use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts to prevent undesirable side effects of cytostatics.  
     
     
         2 . A method for preventing undesirable side effects of cytostatics, which comprises administering an effective amount of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts to a patient in need thereof for preventing said undesirable side effects of cytostatics.

Join the waitlist — get patent alerts

Track US2005187271A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.